Recently, there has been increasing concern in the literature about an increased risk of diabetic ketoacidosis, pancreatitis and bone disorders associated with SGLT2 inhibitors (including EMP) (Perkins et al., 2014; Frampton, 2018; Sampani et al., 2020; Dziadkowiec et al., 2021; Bardhi et al., 2022). The gene discussed is SLC5A2; the disease is bone disorder.